+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 257 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness of delgocitinib cream 20 mgg applied twice daily compared to a non-active cream vehicle in treating adults with mild to severe palmoplantar pustulosis PPP, a condition characterized by pustules on the palms and soles. This phase 2a, double-blind study aims to provide proof-of-concept evidence over a 16-week treatment period. Participants will be randomly assigned to one of two groups one group will apply delgocitinib cream twice daily, and the other will apply a matching vehicle cream twice daily for 16 weeks. The study includes approximately 9 visits over about 18 weeks in total, covering treatment and follow-up periods. Throughout the trial, participants will attend scheduled visits for assessments including skin evaluations, photography confirmation of PPP, and various symptom and quality of life measures. Researchers will monitor improvements using the PPP Area and Severity Index PPPASI and Physician Global Assessment PGA, as well as track adverse events and changes in symptoms like itch and pain. The main outcome is the number of participants achieving at least a 75% improvement in PPPASI score after 16 weeks of treatment.

Age: 18Years +All GendersPhase 2
40 locations
R

Actively Recruiting

Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.

Age: 18Years - 80YearsAll GendersPhase 2
107 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of enicepatide, a dual GLP-1 and GIP receptor agonist, for weight management in adults with obesity or overweight who also have Type 2 diabetes mellitus T2DM. This phase III clinical trial compares multiple doses of enicepatide with a placebo to understand its impact on body weight and diabetes control. Participants will receive once-weekly injections of enicepatide or a placebo using an integrated drug-device combination product. The study has several dosing regimens for enicepatide and includes a placebo group for comparison. Treatment lasts up to 72 weeks, during which participants will receive their assigned injections regularly. Throughout the study, participants will be closely monitored with various assessments including body weight, hemoglobin A1c levels, waist circumference, fasting glucose and insulin levels, cholesterol levels, blood pressure, and quality of life measures. Safety evaluations will also be conducted to track adverse events. The study duration extends through week 72, with multiple outcome measures evaluated from baseline to the end of treatment.

Age: 18Years +All GendersPhase 3
210 locations
E

Actively Recruiting

Researchers are evaluating the effects of enicepatide, a dual GLP-1GIP receptor agonist, for weight management in adults who have obesity or overweight with at least one related health condition, but do not have Type 2 diabetes. The study is a phase III, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of multiple doses of enicepatide compared with placebo. Participants will be randomly assigned to receive one of several dosing regimens of enicepatide or a placebo, administered once weekly using an integrated drug-device combination product. The treatment period lasts for 72 weeks, during which participants will self-administer the injections or receive assistance if needed. The placebo is volume-matched to the active drug to maintain blinding. Throughout the study, participants will have their body weight and other health measures evaluated regularly. Assessments include changes in waist circumference, blood glucose, insulin, cholesterol levels, blood pressure, and health-related quality of life. Safety is monitored by tracking adverse events and questionnaires related to mental health. The primary outcome is the percentage change in body weight from baseline to week 72, and the total participation duration covers this entire period.

Age: 18Years +All GendersPhase 3
209 locations
L

Actively Recruiting

Researchers are studying TAK-279, an oral medicine aimed at reducing inflammation in adults with moderately to severely active Ulcerative Colitis UC or Crohns Disease CD, both serious long-term inflammatory bowel diseases. This study is an extension of previous parent studies and focuses on the long-term safety and tolerability of TAK-279, as well as its effects on reducing bowel inflammation and symptoms over time. Participants who responded to TAK-279 in the parent studies and completed specified treatment periods are invited to continue treatment in this open-label extension trial. All participants will receive Zasocitinib TAK-279 capsules orally for up to 156 weeks about 3 years. This includes those from different parent studies who completed either 12 or 52 weeks of treatment. During the study, participants will visit the clinic around 15 times. Researchers will monitor safety by tracking adverse events, vital signs, lab results, and heart function. They will also evaluate symptom improvements and quality of life using detailed clinical scores and questionnaires. The study aims to understand long-term effects and maintain careful follow-up through regular assessments over the treatment period.

Age: 18Years - 75YearsAll GendersPhase 2
16 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of EscharEx EX-03 5% formulation compared to a placebo in the treatment of Venous Leg Ulcers VLU. This study involves adults with VLU wounds between 2 cm and 25 cm in size, with wound duration from 4 weeks to 12 months. It aims to assess how well EscharEx helps with debridement and wound bed preparation. Participants will be randomly assigned to receive either EscharEx, a sterile powder containing proteolytic enzymes enriched in bromelain, or a placebo gel without the active enzyme. The powder is mixed with sterile water to form a gel that is applied to the wound area. The study includes several periods a screening period with two visits, a daily treatment period of up to eight daily applications over two weeks, followed by weekly wound management visits for up to 12 weeks, and an optional wound closure confirmation period of up to two weeks. After wound closure, participants enter a 12-week monthly visit period to monitor wound closure durability. During the study, participants undergo clinical assessments of wound debridement and closure, including visual evaluations after each application and over the follow-up periods. Researchers will measure the incidence of complete debridement, time to wound closure, and healthy tissue development. Safety and wound healing progress are monitored throughout. The total participation can last up to 29 weeks, with regular visits to ensure detailed monitoring of wound status and treatment effects.

Age: 18Years +All GendersPhase 3
60 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.

Age: 18Years +All GendersPhase 3
174 locations

1-10 of 257

1